ABSTRACT
INTRODUCTION: Anti-N-methyl-D-aspartate (NMDA) encephalitis is a disorder characterized by acute neuro-psychiatric symptoms, appearing mostly after a recent febrile disease, with a gradual progressive course, associated with laboratory or radiologic evidence of active inflammation. Many of the patients will present with a continuous neuro-cognitive disorder which could lead to major morbidity and even mortality. It was recently reported that this disorder can present at childhood as a primary disease or as a secondary complication of herpes simplex infection. Early diagnosis and treatment have significantly improved the patients' prognosis and prevented chronic complications. We will present six pediatric patients at ages 1-14 years, followed from 2011-2014 in Schneider Children's Medical Center and Assaf Harofeh Medical Center due to acute encephalitis, with a clinical course under suspicion for anti-NMDA encephalitis. The article will review the clinical and diagnostic dilemmas and suggested guidelines. Pediatricians should be aware of this new emerging syndrome.
Subject(s)
Anti-N-Methyl-D-Aspartate Receptor Encephalitis/diagnosis , Adolescent , Autoantibodies , Child , Child, Preschool , Early Diagnosis , Female , Humans , Infant , Male , N-Methylaspartate , PrognosisABSTRACT
Time-resolved and steady-state emission characterization of 10-hydroxycamptothecin reveals a rich but less complex proton-transfer behavior than its parent hydroxyquinoline. The electronic effect of the additional electron-withdrawing ring makes the excited-state both less basic and more acidic than the parent and adds to the class of high-acidity excited-state proton donors in photochemistry and photobiology.
Subject(s)
Antineoplastic Agents, Phytogenic/chemistry , Camptothecin/analogs & derivatives , Camptothecin/chemistry , Hydrogen-Ion Concentration , Irinotecan , Kinetics , Protons , Spectrometry, Fluorescence , Structure-Activity Relationship , TitrimetryABSTRACT
UNLABELLED: Four preterm newborn infants with severe multisystem Coxsackie virus B infection were treated with an oral suspension of pleconaril (5 mg/kg per day). The patients had myocarditis, fulminant hepatitis, meningoencephalitis and disseminated intravascular coagulopathy. All four infants recovered, and no adverse effects of the treatment were noted. CONCLUSION: pleconaril needs to be comprehensively evaluated in this population.
